TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37330257
Drug: Light Therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light Therapy
Study: 32472836
Drug: Blue light
Normalized name: Ocuvite Blue Light Mini Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue light therapy
Study: 33516141
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration (500 mL of water two hours before and 2000 mL during the 24 h after CE-CT)
Study: 33516141
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration (sodium bicarbonate 166 mmol/L 3 mL/kg/h starting one hour before and 1 mL/kg/h during the first hour after CE-CT)
Study: 33516141
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and intravenous hydration
Study: 33835842
Drug: Trastuzumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab monotherapy (T)
Study: 33835842
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy (T + C)
Study: 36455006
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (thrice weekly)
Study: 36055919
Drug: Ipilimumab and
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab and Nivolumab (dual immunotherapy)
Study: 33647189
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of ezetimibe/rosuvastatin 10/20 mg
Study: 34844069
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment only (Control Group)
Study: 32554072
Drug: LIFU-mediated gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LIFU-mediated gene delivery to downregulate P2X3 receptor in carotid body (n=14)
Study: 32554072
Drug: LIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIFU treatment alone (n=4)
Study: 32554072
Drug: Cationic microbubbles
Normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cationic microbubbles injection alone (n=4)
Study: 34070014
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g whey protein gel (78 mL/368 kJ) consumed for four days
Study: 32833606
Drug: Goal-Directed Therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-Directed Therapy
Study: 33734131
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with rituximab
Study: 36012027
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly food education sessions based on the Transtheoretical model
Study: 33929094
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acute HIV infection (AHI) screening, contract partner notification, and social contact referral
Study: 35782066
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy with neuromobilization (Group 2)
Study: 35782066
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy without neuromobilization (Group 1)
Study: 34571629
Drug: Vitrectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitrectomy with ILM peeling using heavy brilliant blue G (hBBG) staining
Study: 32769416
Drug: Intensive Interdisciplinary
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Interdisciplinary Pain Treatment (IIPT)
Study: 32769416
Drug: Multimodal Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal Treatment (MMT)
Study: 34314816
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of education on self-management and ergonomic principles, a prefabricated neoprene splint, hand exercises, and diclofenac sodium gel
Study: 34464780
Drug: 3OHB infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3OHB infusion
Study: 32187788
Drug: Advanced pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced pneumatic compression device (APCD), at-home Flexitouch head and neck APCD, used for at least 30 minutes daily
Study: 34480861
Drug: Baricitinib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (4 mg once daily for up to 14 days)
Study: 33853997
Drug: Thrombolysis for
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis for treatment of myocardial infarction
Study: 33853997
Drug: Antithrombotic therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy, lipid lowering, anti-diabetes, anti-obesity, heart failure treatments
Study: 33530298
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (protein-rich beverage powder fortified with calcium 600 mg, vitamin D 400 IU, and vitamin K 55 mcg per daily serving)
Study: 33530298
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement (low-protein non-fortified isocaloric beverage powder)
Study: 35270660
Drug: 12-week motor
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week motor intervention, 60 min per session, twice per week
Study: 34282598
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and Verapamil
Study: 34282598
Drug: Lisinopril alone
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril alone
Study: 35486073
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) with 30-g and 60-g donor feces
Study: 35670873
Drug: Gefapixant 300
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 300 mg BID for 1 week, followed by gefapixant 600 mg BID for 2 weeks
Study: 34371102
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for substance use (up to 12 sessions over 14 weeks)
Study: 34371102
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy targeting depression (CBT-D)
Study: 34371102
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for substance use
Study: 35854374
Drug: Red LED
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red LED therapy
Study: 35854374
Drug: Infrared LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared LED therapy
Study: 33795167
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 88% sucrose (SUC)
Study: 33795167
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of placebo (PLA)
Study: 34238628
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behavioral therapy (I-CBT)
Study: 33173385
Drug: Concurrent CRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent CRT (CCRT)
Study: 33053113
Drug: Escitalopram (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (5‐10 mg once per day, orally; n=49)
Study: 35942814
Drug: Intermittent tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent tiotropium bromide 5 µg for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 27)
Study: 35942814
Drug: Twice-daily fluticasone
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily fluticasone propionate 125 µg for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 25)
Study: 35942814
Drug: As-needed albuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed albuterol sulfate 0.2 mg alone (n = 28)
Study: 33951448
Drug: Selective laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective laser trabeculoplasty (SLT) as a first-line treatment
Study: 33951448
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment as a first-line treatment
Study: 32178692
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omega-3 and plant sterols
Study: 34159762
Drug: Enarodustat 20
Normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Enarodustat 20 mg
Study: 34159762
Drug: Enarodustat 150
Normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Enarodustat 150 mg (supratherapeutic dose)
Study: 34159762
Drug: Moxifloxacin (positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (positive control, 400 mg)
Study: 33028396
Drug: Xanthohumol 24
Normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthohumol 24 mg/day for 8 weeks
Study: 34304146
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (twice-daily, 20-min, 2-mA for 5 days)
Study: 35733213
Drug: Single-dose denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-dose denosumab 60 mg subcutaneous injection
Study: 34228066
Drug: Cytisine (1.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisine (1.5-mg capsules taken 6 times daily for 25 days)
Study: 34228066
Drug: Varenicline (0.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5-mg tablets titrated to 1 mg twice daily for 84 days)
Study: 33674988
Drug: Melatonin 6
Normalized name: melatonin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 6 mg/day for 12 weeks
Study: 32333877
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg cinacalcet per day plus 60 mg denosumab subcutaneously every 6 months (combination group)
Study: 32333877
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg denosumab subcutaneously every 6 months (denosumab group)
Study: 34496116
Drug: Picosecond Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picosecond Nd:YAG laser treatment
Study: 34404907
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion
Study: 37753690
Drug: Niacinamide-containing body
Normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niacinamide-containing body emollients plus cleansing gel (T2)
Study: 32987917
Drug: Abscisic acid
Normalized name: Abscisic Acid
DrugBank: Abscisic Acid (DB16829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abscisic acid (ABA) treatment for 3 months
Study: 37541745
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant 0.7 mg (DEX)
Study: 32798050
Drug: Guideline Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline Daily Amounts (%GDA)
Study: 32243009
Drug: VasH300 (300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: VasH300 (300 mg CWE/day, n = 32)
Study: 32243009
Drug: VasH600 (600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: VasH600 (600 mg CWE/day, n = 32)
Study: 36113537
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg bulevirtide with tenofovir disoproxil fumarate (TDF)
Study: 36113537
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bulevirtide with TDF
Study: 36113537
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bulevirtide with TDF
Study: 33768641
Drug: Skin protection
Normalized name: NeutrapHor 1% Skin Protection Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin protection products (various formulations)
Study: 33009690
Drug: Monthly video
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly video consultations as an add-on to regular care
Study: 32493441
Drug: Anakinra (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100mg daily subcutaneous injection for up to 28 days)
Study: 32493441
Drug: Siltuximab (11mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab (11mg/kg single intravenous injection)
Study: 32493441
Drug: Tocilizumab (8mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8mg/kg single intravenous injection, max 800mg)
Study: 32493441
Drug: Anakinra and
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra and Siltuximab (combination treatment)
Study: 32493441
Drug: Anakinra and
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra and Tocilizumab (combination treatment)
Study: 36018219
Drug: Test eldecalcitol
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test eldecalcitol soft capsules
Study: 36018219
Drug: Reference eldecalcitol
Normalized name: Decalcitrol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference eldecalcitol soft capsules
Study: 32672829
Drug: Cold Atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Atmospheric Plasma (CAP) therapy
Study: 36027496
Drug: KCl supplementation
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KCl supplementation (24mmol thrice daily for 5 days)
Study: 39774588
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg per day)
Study: 32171877
Drug: Laser therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapies (PBT and PDT)
Study: 33092653
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules with the same appearance and characteristics, four times per day for two weeks
Study: 33059754
Drug: Ivermectin treatment
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin treatment
Study: 32387055
Drug: Ranibizumab (PRN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (PRN dosing schedule)
Study: 32387055
Drug: Ranibizumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (monthly dosing schedule)
Study: 36125830
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose immunosuppression
Study: 32795544
Drug: Dronabinol therapy
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol therapy
Study: 34750933
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (NB-UVB, fractional CO2 laser, topical bimatoprost 0.01%)
Study: 34750933
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (NB-UVB, fractional CO2 laser)
Study: 39252484
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI)
Study: 32178568
Drug: Sevoflurane-based combined
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane-based combined intravenous and inhalation anesthesia (group S)
Study: 32178568
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anesthesia (group P)
Study: 32146521
Drug: Uterosacral ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral ligament suspension (ULS)
Study: 33588930
Drug: Visual method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual method of oral hygiene education
Study: 33588930
Drug: Auditory method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory method of oral hygiene education
Study: 33588930
Drug: Kinesthetic method
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesthetic method of oral hygiene education
Study: 35939599
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg/day for 3 cycles)
Study: 36670365
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO)
Study: 34617505
Drug: Cognitive-behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral and well-being therapy (CBT/WBT)
Study: 34973240
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (tamsulosin (0.2 mg/day) plus mirabegron (50 mg/day))
Study: 34085479
Drug: Deep-tissue thread
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep-tissue thread embedding therapy
Study: 34085479
Drug: Shallow-tissue thread
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shallow-tissue thread embedding therapy
Study: 33038432
Drug: Emricasan 25
Normalized name: Emricasán
DrugBank: Emricasan (DB05408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emricasan 25 mg
Study: 35109898
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care alone (which may include mask noninvasive ventilation, high-flow nasal oxygen, or standard oxygen therapy)
Study: 33302654
Drug: Internet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet plus graded diagnosis and treatment strategy
Study: 34032151
Drug: Yukgunja-Tang (YGJT)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yukgunja-Tang (YGJT) administered at 3.0 g twice a day for 4 weeks (total of 56 times)
Study: 35617974
Drug: Ointment
Normalized name: Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment
Study: 34069981
Drug: 4.0 g·d−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g·d−1 β-alanine (BA) for four weeks
Study: 39432252
Drug: Intravenous cangrelor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cangrelor
Study: 35342997
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg once daily (QD) for 6 weeks
Study: 35342997
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily (QD) for 6 weeks
Study: 35342997
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg twice daily (BID) for 2 weeks followed by QD for 4 weeks
Study: 35342997
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg BID for 2 weeks followed by QD for 4 weeks
Study: 35186107
Drug: Lianhua Qingke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lianhua Qingke (LH) tablets (4 tablets, three times a day for 14 days)
Study: 35186107
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment without LH tablets)
Study: 32526195
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg twice daily for 5 days)
Study: 33556032
Drug: EPICOS (tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPICOS (tenofovir disoproxil/emtricitabine vs hydroxychloroquine vs combination therapy vs placebo)
Study: 32503727
Drug: Regadenoson (A2AR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson (A2AR agonist), continuous infusion starting at the time of skin incision, maximum dose of 1.44 µg/kg/min for 12 hours
Study: 35917364
Drug: Single-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose albendazole
Study: 33837574
Drug: Soticlestat oral
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat oral solution, single ascending doses up to 1350 mg
Study: 33837574
Drug: Soticlestat tablets
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat tablets under fed conditions
Study: 33837574
Drug: Soticlestat tablets
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat tablets under fasting conditions
Study: 34655698
Drug: Other antidepressants
Normalized name: Other antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antidepressants (fluoxetine, paroxetine, escitalopram, citalopram, duloxetine, moclobemide, mirtazapine, bupropion)
Study: 36914957
Drug: Aspirin group
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin group
Study: 32045010
Drug: OSA patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSA patients without treatment
Study: 32045010
Drug: OSA patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSA patients with treatment (continuous positive airway pressure or surgery)
Study: 33051276
Drug: Emergency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency treatment with Levetiracetam or Phenytoin
Study: 35487792
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D Supplementation (4,000 IU daily for 30 days)